Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC

With five histone deacetylase (HDAC) inhibitors approved for cancer treatment, proteolysis-targeting chimeras (PROTACs) for degradation of HDAC are emerging as an alternative strategy for HDAC-targeted therapeutic intervention. Herein, three bestatin-based hydroxamic acids (P1, P2 and P3) were desig...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jiangying, Zhao, Wei, Zhao, Chunlong, Liu, Qian, Li, Shunda, Zhang, Guozhen, Chou, C. James, Zhang, Yingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662900/
https://www.ncbi.nlm.nih.gov/pubmed/33126591
http://dx.doi.org/10.3390/molecules25214991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662900/
https://www.ncbi.nlm.nih.gov/pubmed/33126591
http://dx.doi.org/10.3390/molecules25214991

Ejemplares similares